|
 |
Abacavir sulfateThis page contains recent news articles, when available, and an overview of Abacavir sulfate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Abacavir sulfate (when available) Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Abacavir is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. For the treatment of HIV-1 infection, in combination with other antiretroviral agents Mechanism Of Action: Abacavir is a carbocyclic synthetic nucleoside analogue. Intracellularly, Abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. News Articles on Abacavir Gilead Initiates Phase II Clinical Trial Of Integrase-Based ... - 20 Apr 2009 Epzicomâ„¢ (abacavir sulfate/lamivudine) or Trizivir® (abacavir sulfate/lamivudine/zidovudine). Atripla should not be taken with Hismanal® (astemizole), Medical News Today (press release) HIV/AIDS Update - Tentative approval of abacavir sulfate and ... - Mar 31, 2009 ROCKVILLE, Md., March 30, 2009--On March 30, 2009, FDA granted tentative approval for abacavir sulfate and lamivudine tablets, 600 mg / 300 mg, PharmaLive.com (press release) Gilead Initiates Phase II Clinical Trial of Integrase-Based ... - Apr 17, 2009 Epivir ® or Epivir-HBV ® (lamivudine), Epzicomâ„¢ (abacavir sulfate/lamivudine) or Trizivir ® (abacavir sulfate/lamivudine/zidovudine). Business Wire (press release) Gilead initie un essai clinique de Phase II avec un régime ... - Apr 19, 2009 ...l'Epivir ® ou l' Epivir-HBV ® (lamivudine), l'Epzicomâ„¢ (abacavir sulfate/lamivudine) ou le Trizivir ® (abacavir sulfate/lamivudine/zidovudine). Euroinvestor Stakeholders express concern about seized HIV drugs - Mar 15, 2009 According to the organisation, it contained 49kg of abacavir sulfate tablets, a second-line ARV medicine manufactured by Indian pharmaceutical company The Punch NIGERIA: Seizure of drug shipment threatens ARV access - Mar 13, 2009 In a statement on its website, UNITAID explained that the shipment did not contain counterfeit drugs but 49kg of abacavir sulfate tablets, a second-line ARV Reuters AlertNet Concerns Continue Over Generics Drug Seizures As Legality Debates ... - Mar 5, 2009 The shipment, containing 49 kilograms of abacavir sulfate, a second-line HIV/AIDS medication, do not infringe on IP rights and are not counterfeit, Intellectual Property Watch Aurobindo Pharma receives tentative approval for its New Drug ... - 24 Dec 2008 The New Drug Application (NDA) 22-295 provides for the use of Abacavir Sulfate / Lamivudine Tablets 60/30mg for the treatment of HIV infections. Prdomain Business Register (press release), Aurobindo gets approval for Abacavir Sulfate/Lamivudine tab - Dec 22, 2008 The New Drug Application (NDA) 22-295 provides for the use of Abacavir Sulfate / Lamivudine Tablets 60/30mg for the treatment of HIV infections. Moneycontrol.com, Closing Bell - Dec 22, 2008 12:30 pm: Aurobindo Pharma Ltd has received the tentative approval to manufacture and market fixed dosed combination abacavir sulfate / lamivudine tablets Economic Times, Aurobindo Pharma gets nod for Cyclobenzaprine hydrochloride tablets - Sep 26, 2008 Recently, the company received the tentative approval to manufacture and market Abacavir Sulfate / Lamivudine tablets, in the strength of 600mg / 300mg from Myiris.com, Aurobindo Pharma gets USFDA nod for two drugs - Oct 10, 2008 Last month, the company had received two US FDA approval for manufacturing and marketing Didanosine Delayed Release capsules and Abacavir Sulfate tablets, Hindu, Aurobindo Pharma gets nod for Didanosine Delayed Release Capsules - Sep 25, 2008 Earlier this month, the company received tentative approval from US FDA, to manufacture and market Abacavir Sulfate or Lamivudine tablets, TopNews, Aurobindo gets approval for Abacavir Sulfate/Lamivudine tab Sep 8, 2008 Aurobindo Pharma Limited is pleased to announce that it has received the tentative approval to manufacture and market Abacavir Sulfate / Lamivudine tabletsMoneycontrol.com (press release), FDA Announces HIV/AIDS Update Sep 4, 2008 4, 2008--On September 3, 2008, FDA granted tentative approval for the first generic combination formulation of abacavir sulfate and lamivudine tablets,PharmaLive.com (press release), Closing Bell Sep 8, 2008 10:40 am: Aurobindo Pharma has received the tentative approval to manufacture and market abacavir sulfate / lamivudine tablets 600mg/300mg from the US FoodEconomic Times, ç±³FDAã€?インド製薬会社ã?®ã‚¸ã‚§ãƒ?リックHIV治療薬を許å?¯ Sep 9, 2008 ...米国食å“?医薬å“?局（FDA）ã?‹ã‚‰HIVã?®æ²»ç™‚ã?«ç”¨ã?„られるアãƒ?カビル硫酸塩（Abacavir Sulfate）ã?¨ãƒ©ãƒŸãƒ–ジン（Lamivudine）ã?®è£½é€ ・販売ã?®æš«å®šæ‰¿èª?ã‚’å¾—ã?Ÿã?¨ç™ºè¡¨ã?—ã?Ÿã€‚IBTimes, Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of ... - 06 Aug 2008 Abacavir sulfate is a nucleoside reverse transcriptase inhibitor with a proven safety and efficacy profile as part of an HIV treatment regimen. MarketWatch FDA Announces Important Safety-Related Label Update for Ziagen ... - Jul 23, 2008 ROCKVILLE, Md., July 23, 2008--On July 18, 2008, FDA approved changes to the package insert for Ziagen (abacavir sulfate) highlighting information about the PharmaLive.com (press release), Updated box warning for abacavir treatments - Jul 25, 2008 The boxed warning for GlaxoSmithKline's Ziagen (abacavir sulfate) and other abacavir-containing drugs has been updated to warn about the increased risk of Prescribing Reference, Gilead Sciences And Merck & Co., Inc. Agree To Register And ... - Aug 4, 2008 Epivir® or Epivir-HBV® (lamivudine), Epzicom® (abacavir sulfate/lamivudine), or Trizivir® (abacavir sulfate/ lamivudine/zidovudine). Medical News Today (press release), Serious Reactions in Some to Ziagen, Abacavir, FDA Warns - Jul 25, 2008 Also, HLA-B*5701-negative patients may also develop an HSR to Abacavir The FDA approved changes to Ziagen’s (abacavir sulfate) package insert highlighting Newsinferno.com, Genetic Screening Recommended Before Abacavir HIV Therapy - Jul 25, 2008 ...reactions (HSRs) to abacavir sulfate (Ziagen, GlaxoSmithKline), the US Food and Drug Administration (FDA) advised healthcare professionals yesterday. Medscape (subscription) Study Suggests Common AIDS Drug Nearly Doubles Heart Attack Risk - Apr 2, 2008 By MARIA CHENG AP Medical Writer AP A pharmacist in Jersey City, NJ, counts Ziagen(r) (abacavir sulfate) tablets, a new drug that was recently approved by ABC News European Commission Approves ATRIPLA(R) (efavirenz 600 mg ... - Dec 17, 2007 Epivir(R) or Epivir-HBV(R) (lamivudine), Epzicom(TM) (abacavir sulfate/lamivudine), or Trizivir(R) (abacavir sulfate/lamivudine/zidovudine). CNNMoney.com Gilead Announces 48-Week Data Evaluating Switching from Combivir ... - Oct 29, 2007 ...(lamivudine/zidovudine), Epivir or Epivir-HBV (lamivudine), Epzicom (abacavir sulfate/lamivudine) or Trizivir (abacavir sulfate/lamivudine/zidovudine). Business Wire (press release), European CHMP Issues Positive Opinion For ATRIPLA(R) (Efavirenz ... - Oct 22, 2007 Epivir(R) or Epivir-HBV(R) (lamivudine), Epzicom(TM) (abacavir sulfate/lamivudine), or Trizivir(R) (abacavir sulfate/lamivudine/zidovudine). Medical News Today (press release), GSK withdraws Trizivir patent application ‘in public interest’ - Oct 9, 2007 Trizivir is a fixed-dose combination tablet containing three drugs, lamivudine, zidovudine and abacavir sulfate. Glaxo had received the US Food and Drug Livemint, Genetic test reduces AIDS drug side - Jul 25, 2007 The Australian,The test reveals if a patient is likely to develop life-threatening side effects to one of the most frequently used HIV drugs, abacavir sulfate, 144-Week Data from Gilead's Study 934 Comparing Truvada to ... - Jul 23, 2007 PharmaLive.com (press release),Epivir(R) or Epivir-HBV(R) (lamivudine), Epzicom(TM) (abacavir sulfate/lamivudine) or Trizivir(R) (abacavir sulfate/lamivudine/zidovudine). FDA Announces Tentative Approval of Generic Abacavir Sulfate Tablets - Apr 6, 2007 PharmaLive.com (press release),Abacavir sulfate is a member of the class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs), which help keep the AIDS virus from FDA Announces Important Notice About Combivir and Ziagen - Apr 10, 2007 PharmaLive.com (press release),We would like to call to your attention an apparent third-party tampering that caused misbranding of Ziagen® (abacavir sulfate) Tablets as Combivir® FDA Grants Tentative Approval for Matrix's Antiretroviral Drug ... - Apr 12, 2007 Kaiser network.org,India-based Matrix Laboratories recently received tentative approval from FDA to produce 300 milligram tablets of the antiretroviral drug abacavir sulfate, FDA Alerts Pharmacists About Mislabeling of HIV Drugs - Apr 11, 2007 MedPage Today,A letter sent to pharmacists said the incidents, which involved abacavir sulfate (Ziagen) and a combination of lamvudine and zidovudine (Combivir), Isolated Case of Counterfeit Combivir on the Market - Apr 12, 2007 Facts and Comparisons,GlaxoSmithKline is informing health care professionals of an incident of misbranding of Ziagen (abacavir sulfate) as Combivir (lamivudine/zidovudine). FDA Safety Changes: Ortho Evra, Avastin, Trizivir - Dec 13, 2006 Medscape (subscription)On August 11, the FDA approved safety labeling revisions for abacavir sulfate/lamivudine/zidovudine tablets (Trizivir, made by GlaxoSmithKline) to warn of FDA List Serve - Tentative approval of generic abacavir sulfate Nov 7, 2006 6, 2006--The Food and Drug Administration, on November 6, 2006, granted tentative approval for a generic formulation of abacavir sulfate tablets, 300 mg ... -PharmaLive.com (press release), New Data Reinforce Efficacy of Abacavir Sulfate/Lamivudine ... Oct 12, 2006 SAN FRANCISCO, CA -- October 12, 2006 -- The HIV medication Trizivir(R) (abacavir sulfate, lamivudine, and zidovudine) administered twice daily provides ... -DG News Cipla receives tentative approval from US for AIDS drug Nov 7, 2006 Cipla (Q, N,C,F)* has received tentative approval from the US Food and Drug Administration to sell AIDS drug `abacavir sulfate` in tablet form, reports ... -Myiris.com, GlaxoSmithKline and Vertex Pharmaceuticals Announce Virologic and ... Oct 12, 2006 ...with HIV-1. Patients were randomized to receive either Lexiva/r or lopinavir/r twice daily, administered with Epzicom(TM) (abacavir sulfate and lamivudine ... -DG News Updated HIV Treatment Guidelines Now Include Three GSK HIV ... Aug 13, 2006 In the guidelines, EPZICOM(TM) (abacavir sulfate and lamivudine) and COMBIVIR(R) (lamivudine and zidovudine) are both recommended nucleoside reverse ... -International News Service Updated HIV treatment guidelines now include three GSK HIV ... Aug 14, 2006 In the guidelines, epzicomâ„¢ (abacavir sulfate and lamivudine) and combivir® (lamivudine and zidovudine) are both recommended nucleoside reverse ... -WebWire Updated HIV Treatment Guidelines Now Include Three GSK HIV ... Aug 13, 2006 In the guidelines, EPZICOM(TM) (abacavir sulfate and lamivudine) and COMBIVIR® (lamivudine and zidovudine) are both recommended nucleoside reverse ... -Yahoo! News FDA Announces Tentative Approval of Lamivudine/sidovudine Co ... Jul 26, 2006 The Food and Drug Administration granted tentative approval on July 26, 2006 for lamivudine/zidovudine tablets co-packaged with abacavir sulfate tablets for ... -PharmaLive.com Aurobindo Pharma receives US FDA approval for Abacavir Sulfate ... Jul 1, 2006 ...infection. Abacavir sulfate oral solution is the version of Ziagen Solution, an anti-HIV medication manufactured by GlaxoSmithKline. -Myiris.com Generic pediatric AIDS Drug gets US OK Jun 28, 2006 WASHINGTON, June 28 (UPI) -- The US Food and Drug Administration has tentatively approved the generic version of Abacavir Sulfate Oral Solution for use by ... -United Press International Generic Pediatric AIDS Drug Gets US OK Jun 28, 2006 The US Food and Drug Administration has tentatively approved the generic version of Abacavir Sulfate Oral Solution for use by pediatric AIDS victims. ... -International News Service FDA Gives Tentative Approval For Another First Time Generic ... Jun 30, 2006 FDA) within the US Department of Health and Human Services (HHS) today announced the tentative approval of the generic version of Abacavir Sulfate (a bak' a vir ... -Medical News Today FDA gives tentative approval for generic pediatric AIDS drug Jun 27, 2006 The Food and Drug Administration (FDA) today announced the tentative approval of the generic version of Abacavir Sulfate Oral Solution, 20 mg (base)/mL ... -News-Medical.net Brand Names/Synonyms: Abacavir sulfate is also known by the following brand names and/or synonyms1592U89; ABC; Abacavir; Abacavir [Inn]; Ziagen Drug Category: Abacavir sulfate is categorized under the following by the FDA: Anti-HIV Agents; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; ATC:J05AF06 Dosage Forms: SOLUTION; TABLET Absorption: Rapid and extensive after oral administration (83% bioavailability) Interactions: -->Interactions for Abacavir: Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. Abacavir has no effect on the pharmacokinetic properties of ethanol. Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients. Chemical IUPAC Name: [4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-1-cyclopent-2-enyl]methanol : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |